Figure 1
From: Tumor–associated antigens identified by mRNA expression profiling as tumor rejection epitopes
CTL development in vivo against SM7-derived RAD50 peptides. Groups of three mice were immunized once subcutaneously with individual peptides including a helper peptide. Splenocytes were peptide challenged ex vivo at day 10 and assayed for CTL activity five days later. A, Generation of CTLs against RAD50 peptides. B, CTL reactivity against SM7 thymoma cells pulsed with the RAD50 peptides. C, CTL reactivity against non-pulsed SM7 thyoma cells (see Table 1 for peptide name, sequence and MHC-I binding affinity).